Last reviewed · How we verify
Geref — Competitive Intelligence Brief
marketed
sermorelin
Growth hormone-releasing hormone receptor
Hematology
Live · refreshed every 30 min
Target snapshot
Geref (sermorelin).
Comparator set (2 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Geref TARGET | sermorelin | marketed | sermorelin | Growth hormone-releasing hormone receptor | 1990-01-01 | |
| Egrifta | TESAMORELIN ACETATE | Theratechnologies | marketed | Growth Hormone Releasing Factor Analog | Growth hormone-releasing hormone receptor | 2010-01-01 |
| Taxotere | Docetaxel | Sanofi | marketed | Microtubule Inhibitor [EPC] | Growth hormone-releasing hormone receptor | 1996-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Taxotere · 10842770 · Formulation · US
- — Taxotere · 9308195 · Formulation · US
- — Taxotere · 9763880 · Method of Use · US
- — Taxotere · 8940786 · Formulation · US
- — Taxotere · 10398785 · Formulation · US
- — Taxotere · 12090135 · Formulation · US
- — Taxotere · 11419842 · Formulation · US
- — Taxotere · 12090134 · Formulation · US
Sponsor landscape (sermorelin class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Geref CI watch — RSS
- Geref CI watch — Atom
- Geref CI watch — JSON
- Geref alone — RSS
- Whole sermorelin class — RSS
Cite this brief
Drug Landscape (2026). Geref — Competitive Intelligence Brief. https://druglandscape.com/ci/sermorelin. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab